TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31657590

Group type: EXPERIMENTAL
Intervention: ENHANCE intervention program (12-week comprehensive program)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: ENHANCE intervention (original treatment condition)
Number of subjects: 155
Study: 30112788

Group type: EXPERIMENTAL
Intervention: Family Member Education Program (FMEP)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 144
Study: 28116876

Group type: EXPERIMENTAL
Intervention: EPI® technique in combination with a standardized APT program
Number of subjects: 24

Group type: COMPARATOR
Intervention: APT program
Number of subjects: 24
Study: 26162594

Group type: EXPERIMENTAL
Intervention: I-gel size 2 (group I)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CLMA size 2 (group II)
Number of subjects: 0
Study: 22251226

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly (QW)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly (BIW)
Number of subjects: 0
Study: 21641077

Group type: EXPERIMENTAL
Intervention: Ablative fractional laser therapy (FLT) at 10 mJ/microbeam, coverage 35% to 45%, and topical bleaching
Number of subjects: 11

Group type: COMPARATOR
Intervention: Topical bleaching alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ablative fractional laser therapy (FLT)
Number of subjects: 11
Study: 18516011

Group type: EXPERIMENTAL
Intervention: 10 day-sequential therapy (20 mg of omeprazole, 1.0 g of amoxicillin for the first 5 days, followed by 20 mg of omeprazole, 500 mg of clarithromycin, 500 mg of metronidazole for the remaining 5 days)
Number of subjects: 158

Group type: COMPARATOR
Intervention: PPI-based triple therapy (20 mg of omeprazole, 1.0 g of amoxicillin, 500 mg of clarithromycin for 1 week)
Number of subjects: 158
Study: 16521033

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 58
Study: 12914361

Group type: EXPERIMENTAL
Intervention: Ultracision (ultrasonic hook)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional hemostasis
Number of subjects: 34
Study: 10541299

Group type: COMPARATOR
Intervention: Epoetin alfa (100 U/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: NESP (equivalent peptide mass) intravenous
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: NESP (equivalent peptide mass) subcutaneous
Number of subjects: 11
Study: 7604351

Group type: EXPERIMENTAL
Intervention: Automated Percutaneous Lumbar Discectomy (APLD)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Lumbar Microdiscectomy
Number of subjects: 71
Study: 2233588

Group type: EXPERIMENTAL
Intervention: Peroral colonic lavage
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Senna preparation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combined laxative agent
Number of subjects: 90
Study: 263355

Group type: EXPERIMENTAL
Intervention: L-dopa (1.0 g)
Number of subjects: 14
Study: 31422201

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 95
Study: 28318988

Group type: EXPERIMENTAL
Intervention: Butorphanol (2 mg kg−1 intravenously)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Morphine (2 mg kg−1 intravenously)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 168
Study: 25311220

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT) after breast-conserving surgery (BCS) for DCIS.
Number of subjects: 1046
Study: 23102521

Group type: EXPERIMENTAL
Intervention: Acupuncture (up to ten sessions over 3 months)
Number of subjects: 113
Study: 19602734

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 46
Study: 17877624

Group type: EXPERIMENTAL
Intervention: Active bleaching treatment for teeth whitening
Number of subjects: 172
Study: 15086494

Group type: EXPERIMENTAL
Intervention: Conventional bicarbonate dialysis (BD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetate-free biofiltration (AFB)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Model simulations
Number of subjects: 12
Study: 12471289

Group type: COMPARATOR
Intervention: Endurance Training (ET)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined Endurance and Strength Training (CT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of CT vs ET
Number of subjects: 20
Study: 9806587

Group type: EXPERIMENTAL
Intervention: Initial serum hCG measurements
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Repeated serum hCG measurements
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Serum hCG concentration rise
Number of subjects: 354
Study: 7895756

Group type: EXPERIMENTAL
Intervention: Ringer solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: serum preparation (BISEKO)
Number of subjects: 20
Study: 2565392

Group type: EXPERIMENTAL
Intervention: 150 mg of metoprolol p.o.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 80 mg of oxprenolol p.o.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 478263

Group type: EXPERIMENTAL
Intervention: Plasma ribonuclease activity test
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 62

Group type: COMPARATOR
Intervention: Patients in remission from ovarian cancer
Number of subjects: 62
Study: 30940676

Group type: EXPERIMENTAL
Intervention: Liberal platelet transfusion (to maintain a platelet count >100,000 per µL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard platelet transfusion criteria
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Liberal platelet transfusion
Number of subjects: 44
Study: 28117496

Group type: EXPERIMENTAL
Intervention: Super‐pulsed fractional CO2 laser applications (10,600 nm, density of 20%, energy of 10 mJ, scanner of 03 × 03 mm, pulse repetition time of 0.3 seconds)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Silicone gel
Number of subjects: 42
Study: 25889705

Group type: EXPERIMENTAL
Intervention: Parotid-sparing conformal radiotherapy
Number of subjects: 0
Study: 24021602

Group type: EXPERIMENTAL
Intervention: Physical vasomotion stimulation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 21831465

Group type: EXPERIMENTAL
Intervention: RT-CT (radiotherapy and chemotherapy) - 64Gy in 5 weeks with synchronous CDDP 100mg/m² on days 2, 16, and 30 and 5FU 1000mg/m² on days 1-5 and 29-33, followed by two adjuvant cycles of CDDP-5FU for good responders.
Number of subjects: 109

Group type: COMPARATOR
Intervention: Accelerated RT - 64Gy in 3 weeks (control arm).
Number of subjects: 109
Study: 19720908

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg by mouth twice daily for 4 to 6 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 64
Study: 17043926

Group type: EXPERIMENTAL
Intervention: 10/20 mg Memantine per day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 40
Study: 16481295

Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2) on days 1 and 8, and Carboplatin (target AUC of 5.0 mg/ml) on day 1, in a 21‐day cycle
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gemcitabine and Carboplatin combination chemotherapy
Number of subjects: 20
Study: 12934847

Group type: EXPERIMENTAL
Intervention: DTaP-IPV/Hib combination vaccine administered in a single injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Separate injection of DTaP-IPV and Hib
Number of subjects: 60
Study: 10546697

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg dose of recombinant leptin
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 0.30 mg/kg dose of recombinant leptin
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg dose of recombinant leptin
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: All doses of recombinant leptin
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Injection site reactions
Number of subjects: 127
Study: 8932973

Group type: EXPERIMENTAL
Intervention: Remote clinic monitoring and visual function tester certification via phone calls and centralized systems.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Telephone certification of visual function technicians by regional coordinators.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Monthly phone calls for clinic monitoring and annual patient exams.
Number of subjects: 200
Study: 2009034

Group type: EXPERIMENTAL
Intervention: Clonidine (3 to 5 micrograms/kg per day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 47
Study: 7036334

Group type: EXPERIMENTAL
Intervention: Guanfacine (average dose 2.6 mg daily)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Alpha-methyldopa (average dose 750 mg daily)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Alpha-methyldopa
Number of subjects: 78
Study: 30978556

Group type: EXPERIMENTAL
Intervention: Early aortic valve replacement
Number of subjects: 400

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 400
Study: 28063815

Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 4685

Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 4685
Study: 26365454

Group type: EXPERIMENTAL
Intervention: Music intervention along with lifestyle modifications (listening to raga bhimpalas played on flute for 15min daily for at least 5 days/week for 3 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lifestyle modifications only (according to Joint national committee VII guidelines)
Number of subjects: 100
Study: 23578975

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) treatment involving 3 periods of 5‐min occlusion at 220 mmHg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment involving 3 periods of 5‐min occlusion at 50 mmHg
Number of subjects: 25
Study: 21896877

Group type: EXPERIMENTAL
Intervention: Guava juice (300 mL containing ∼200 mg of ascorbic acid)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (guava-flavored juice free of AA)
Number of subjects: 95
Study: 19947275

Group type: EXPERIMENTAL
Intervention: Combined auricular point injection and superficial anesthesia (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Simple superficial anesthesia (Group B)
Number of subjects: 40
Study: 17906168

Group type: COMPARATOR
Intervention: Experimental induction of good or bad news from research on aging (Study 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interest in science (Study 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desire to control the 'when and how' of one's death
Number of subjects: 0
Study: 15295946

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D plus E/HRT
Number of subjects: 49

Group type: COMPARATOR
Intervention: Calcium and vitamin D only
Number of subjects: 49
Study: 11677705

Group type: EXPERIMENTAL
Intervention: In-practice educational session plus information pack (Group A)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Information pack alone (Group B)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Neither educational session nor information pack (Group C - Control)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Reported confidence score (Group A)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Reported confidence score (Group B)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Reported confidence score (Group C - Control)
Number of subjects: 426
Study: 9039200

Group type: EXPERIMENTAL
Intervention: Butenafine 1% cream applied twice daily for 1 week
Number of subjects: 402

Group type: COMPARATOR
Intervention: Vehicle applied twice daily for 1 week
Number of subjects: 402
Study: 7705374

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU d‐1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g d‐1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Vitamin D and Calcium supplementation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 55
Study: 3312033

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 92

Group type: COMPARATOR
Intervention: Cefazolin/Tobramycin
Number of subjects: 92
Study: 31246050

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) followed by Imagery Rehearsal Therapy (IRT) and Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prolonged Exposure (PE) followed by supportive care therapy (SCT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) followed by IRT and CBT-I
Number of subjects: 100
Study: 31206763

Group type: EXPERIMENTAL
Intervention: Lingual strength training (LST), performed five times a week for 6 weeks, using tongue-to-palate resistance exercise method (isometric and isotonic exercise)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 28045559

Group type: EXPERIMENTAL
Intervention: Water aerobics exercise (45 minutes, 70%–75% HRmax)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control session (no exercise for 45 minutes)
Number of subjects: 50
Study: 26102252

Group type: EXPERIMENTAL
Intervention: Dilmapimod (10mg continuous infusion over 24 hours)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Dilmapimod (4-hour IV infusion)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Dilmapimod (24-hour IV infusion)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Overall study population
Number of subjects: 77
Study: 23384733

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine (0.57 mg kg(‐1) h(‐1) for 1 h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: morphine (0.065 mg kg(‐1) h(‐1) for 1 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 21904289

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 78
Study: 19460848

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 16456831

Group type: EXPERIMENTAL
Intervention: Daclizumab (2, 2, and 1 mg/kg on days 1, 3, and 8 posttransplant)
Number of subjects: 30
Study: 15156439

Group type: EXPERIMENTAL
Intervention: 15 mg/kg per day intravenous streptomycin, kanamycin, or amikacin
Number of subjects: 87

Group type: COMPARATOR
Intervention: 25 mg/kg 3 times per week intravenous streptomycin, kanamycin, or amikacin
Number of subjects: 87
Study: 11873034

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 110

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 110
Study: 9755379

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study: 7618049

Group type: EXPERIMENTAL
Intervention: Intravesical infusion of saline solution containing 10 microM capsaicin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vehicle (control group)
Number of subjects: 21
Study: 2529295

Group type: EXPERIMENTAL
Intervention: 6 mg of alprazolam
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 2 mg of alprazolam
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 225 mg of imipramine
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 401600

Group type: EXPERIMENTAL
Intervention: Glucagon (2 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propantheline bromide (Pro-Banthine, 30 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (solvent solution)
Number of subjects: 48
Study: 31822353

Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided erector spinae plane block with 40ml of 0.25% bupivacaine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bilateral ultrasound-guided erector spinae plane block with 40ml of saline (Control)
Number of subjects: 41
Study: 28282501

Group type: EXPERIMENTAL
Intervention: Mite-impermeable bed encasings (active group)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo bed encasings (control group)
Number of subjects: 284
Study: 25497258

Group type: EXPERIMENTAL
Intervention: Targeted performance feedback reports (5 reports provided)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard performance feedback reports
Number of subjects: 149
Study: 23295713

Group type: EXPERIMENTAL
Intervention: Group E (thoracic epidural‐based analgesia)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Group P (systemic opioid‐based analgesia)
Number of subjects: 26
Study: 20974645

Group type: EXPERIMENTAL
Intervention: Pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially with seasonal virosomal-adjuvanted influenza vaccine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered simultaneously with seasonal virosomal-adjuvanted influenza vaccine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Seasonal virosomal-adjuvanted influenza vaccine (administered sequentially or simultaneously)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Simultaneous administration of both vaccines
Number of subjects: 64

Group type: COMPARATOR
Intervention: Pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially
Number of subjects: 64
Study: 19493713

Group type: COMPARATOR
Intervention: Amoxicillin 1g, Metronidazole 500 mg b.i.d., Bismuth 240 mg b.i.d., Omeprazole 40 mg q.i.d. for 2 weeks
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Amoxicillin 1g, Metronidazole 500 mg b.i.d., Bismuth 240 mg b.i.d., Omeprazole 40 mg q.i.d. plus 500 mg vitamin C per day for 2 weeks
Number of subjects: 312
Study: 17251236

Group type: EXPERIMENTAL
Intervention: Indacaterol 200 microg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Indacaterol 50 microg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Indacaterol 100 microg
Number of subjects: 42
Study: 15139065

Group type: EXPERIMENTAL
Intervention: High-dose thiotepa (750 mg/m2) and carboplatin (1600 mg/m2) with autologous stem cell transplantation (ASCT)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-dose thiotepa and carboplatin with ASCT
Number of subjects: 21
Study: 11059262

Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 13
Study: 9374097

Group type: EXPERIMENTAL
Intervention: Doxorubicin and paclitaxel combination therapy, total doxorubicin dose limited to 360 mg/m2.
Number of subjects: 0
Study: 1398238

Group type: EXPERIMENTAL
Intervention: Aspirin EC 300 mg once daily for seven days before cholecystectomy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no aspirin treatment)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 4019551

Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diatrizoate (Renografin‐76)
Number of subjects: 60
Study: 31701623

Group type: EXPERIMENTAL
Intervention: Educational intervention by pharmacist focusing on diet and exercise
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 118
Study: 29651635

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (3 capsules totaling 9 × 10^13 colony-forming units per day of Streptococcus thermophilus, Lactobacillus acidophilus, and Bifidobacteria longum)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 29375915

Group type: EXPERIMENTAL
Intervention: Real Vagus Nerve Stimulation (VNS) with robotic rehabilitation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham Vagus Nerve Stimulation (VNS) with robotic rehabilitation
Number of subjects: 14
Study: 25582875

Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation (CB-AdvA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Radiofrequency catheter ablation (RFCA)
Number of subjects: 100
Study: 23915250

Group type: EXPERIMENTAL
Intervention: EBMeDS reminders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care process
Number of subjects: 0
Study: 21921743

Group type: COMPARATOR
Intervention: Pressure garment therapy alone
Number of subjects: 43

Group type: COMPARATOR
Intervention: Silicone spray and compression
Number of subjects: 43

Group type: COMPARATOR
Intervention: Silicone sheeting and compression
Number of subjects: 43

Group type: COMPARATOR
Intervention: Compression alone
Number of subjects: 43
Study: 19810584

Group type: EXPERIMENTAL
Intervention: Yoga-nidra with oral hypoglycaemic
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral hypoglycaemic alone
Number of subjects: 41
Study: 16759045

Group type: EXPERIMENTAL
Intervention: 20 microg Z-100
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 40 microg Z-100
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 14715189

Group type: EXPERIMENTAL
Intervention: Perindopril/Indapamide (Per/Ind)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study: 11513913

Group type: EXPERIMENTAL
Intervention: Early intravenous bolus injection of ACTH-(1-24)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 9028722

Group type: EXPERIMENTAL
Intervention: Pramlintide 25 micrograms/h
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8383517

Group type: EXPERIMENTAL
Intervention: Terbutaline (beta 2-adrenoceptor agonist)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Xamoterol (partial beta 1-agonist)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 10